Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

@article{Aymerich2018CannabinoidPI,
  title={Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system},
  author={Maria S Aymerich and Ester As{\'o} and Miguel A Abellanas and Rosa Mar{\'i}a Tol{\'o}n and Jos{\'e} Antonio Ramos and Isidre Ferrer and Julián Romero and Javier Fern{\'a}ndez-Ruiz},
  journal={Biochemical Pharmacology},
  year={2018},
  volume={157},
  pages={67–84}
}
View on Wolters Kluwer
diposit.ub.edu
57 Citations
Background Citations
16
Methods Citations
1

Figures from this paper

57 Citations

Citation Type

Citation Type

Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis
TLDR
The evidence accumulated so far at the preclinical level supports the need to soon move towards the patients and initiate clinical trials to confirm the potential of cannabinoid‐based medicines as disease modifiers in ALS.
Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions
TLDR
These reviews delineate the reported evidence from the literature on the neuromodulatory role of the endocannabinoid system and expression of cannabinoid receptors in symptomatology, cause, and treatment of PD progression, wherein cannabinoid (CB) signalling experiences alterations of biphasic pattern during PD progression.
Cannabinoid Drugs-Related Neuroprotection as a Potential Therapeutic Tool Against Chemotherapy-Induced Cognitive Impairment
TLDR
The neuroprotective role of the ECS, well described in other cognitive-related neuropathologies, seems to be able to reduce the activation of pro-inflammatory cytokines involved in the neuroinflammatory supraspinal processes underlying CICI.
Effect of Cannabidiol on the Neural Glyoxalase Pathway Function and Longevity of Several C. elegans Strains Including a C. elegans Alzheimer's Disease Model.
TLDR
It is determined that a limited amount of Cannabidiol can prevent methylglyoxal-mediated cellular damage through enhancement of the neural glyoxalase pathway and extend the lifespan and survival of C. elegans, including a transgenic C. coli strain modeling Alzheimer's disease.
Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease.
Potentiation of amyloid beta phagocytosis and amelioration of synaptic dysfunction upon FAAH deletion in a mouse model of Alzheimer's disease
TLDR
The chronic enhancement of the endocannabinoid tone rescues hippocampal synaptic plasticity in the 5xFAD mouse model and supports the therapeutic potential of modulating, rather than suppressing, neuroinflammation in Alzheimer's disease.
Possible therapeutic applications of cannabis in the neuropsychopharmacology field
Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology
TLDR
How cannabinoids act as potent regulators of NSC biology and their potential to modulate several neurogenic features in the context of pathophysiology are reviewed.
Role of cannabinoids in alcohol-induced neuroinflammation
Cannabinoids as Glial Cell Modulators in Ischemic Stroke: Implications for Neuroprotection
TLDR
Current findings on the potential promising contribution of the endocannabinoid system pharmacological manipulation in glial cells for the treatment of ischemic stroke are recapitulate.
...
...

References

SHOWING 1-10 OF 317 REFERENCES
Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target
TLDR
The modulation of CB2 receptor signaling may represent a promising therapeutic target with minimal psychotropic effects that can be used to modulate endocannabinoid-based therapeutic approaches and to reduce neuronal degeneration.
Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease
The endocannabinoid system as a target for the treatment of motor dysfunction
TLDR
This article will review the available data regarding the relationship between the cannabinoid system and basal ganglia activity, both in healthy and pathological conditions and will try to identify future lines of research expected to increase current knowledge about the potential therapeutic benefits of targeting this system in PD, HD and other basal Ganglia disorders.
The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis
Differential upregulation of the cannabinoid CB2 receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
TLDR
A comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy is provided.
Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease
CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease
TLDR
Accumulated evidence suggests a role for CB2 receptors in Alzheimer's disease (AD) and indicates their potential as a therapeutic target against this neurodegenerative disease.
Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
TLDR
The cellular and molecular mechanisms, and the signaling pathways, underlying these neuroprotective properties, including the control of glutamate homeostasis, calcium influx, the toxicity of reactive oxygen species, glial activation and other inflammatory events; and the induction of autophagy are described.
Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease
...
...